General Information of Drug (ID: DMD2L1U)

Drug Name
OBI-888
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
UNII
JI5TBH62QP
DrugBank ID
DB18289
TTD ID
D59OTG

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Globohexaosylceramide (Globo H) TT4UXTG NOUNIPROTAC Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03573544) This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of OBI Pharma.